Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
Posted by rob on March 28, 2010 under Uncategorized | 
Comments are off for this article
 |
Related Articles |
Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
Leuk Res. 2010 Apr;34(4):e91-3
Authors: Faber E, Mojzikova R, Plachy R, Rozmanova S, Stastny M, Divoka M, Jarosova M, Indrak K, Divoky V
PMID: 19811824 [PubMed - indexed for MEDLINE]